Q3 Revenue Jumps 34% to $91M, Full-Year Guidance Raised Sharply
OMDA sits 94% above its 52-week low of $10.28.
Summary
Omada beat its own trajectory with Q3 revenue of $91.3M, up 34% year over year from $68.0M, and swung to net income of $6.6M from a $3.2M loss a year ago. Gross margin expanded to 76% from 66%, and Adjusted EBITDA came in at $12.4M versus $2.4M. The bigger news is guidance: full-year revenue is now $344M-$346M (from $334M-$340M) and Adjusted EBITDA is $32M-$34M, roughly five and a half times last year's level and well above the prior $21M-$27M range. Total Members reached 1.1 million, up 36%, with average tenure extending to about two years and four months. This follows the September disclosure that management sees at least 20% annual revenue growth — the new midpoint implies about 33% for 2026, so the growth story is accelerating rather than fading. Cash stands at $243M with positive free cash flow of $2.5M through nine months.
At the time of this announcement, OMDA was trading at $19.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $10.28 to $25.54. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.